Meta Information

ID:empagliflozin

Name:Empagliflozin

Schema Version:1.5

Alternate Names

• Jardiance

Active Compound

empagliflozin

Intervention Type

therapeutic_agent

Delivery

Route:

oral

Scope:

• systemic

Regulatory Status

• us:rx_drug
• eu:rx_drug

Indication

Focus:

• disease_treatment
• healthspan

Description:

Empagliflozin is an SGLT2 inhibitor that causes the kidneys to excrete excess glucose, thereby lowering blood sugar and blood pressure. Its healthspan relevance stems from robust clinical trial eviden... | Targeting systemic metabolic health and cellular energy regulation to potentially slow age-related cardiovascular and renal decline.

Typical Protocol

• Standard clinical doses are 10 mg or 25 mg taken once daily in the morning.
• Off-label healthspan use often mirrors the lower clinical dose of 10 mg daily.

Expected Cost Mean

Low Cost:

50

High Cost:

150

Cost Type:

monthly

Description:

Monthly cost for generic versions; often covered by insurance for approved indications.

Summary

Initially developed as a diabetes medication, empagliflozin works by causing the kidneys to remove excess blood sugar through urine. However, extensive clinical evidence revealed that it also provides powerful protection for the heart and kidneys, two organs highly susceptible to age-related decline. This has prompted its emerging use for healthspan optimization, as its broader metabolic effects—including lowered blood pressure and a mild state of ketosis—help shield these key organ systems from the damage that drives age-related disease.

Purpose

SGLT2 inhibitor that improves metabolic health and organ protection.

Card Summary

An SGLT2 inhibitor that lowers blood glucose and protects the heart and kidneys, mimicking some metabolic benefits of fasting.

Drug Class

sglt2_inhibitors

Drugs In Class

Empty Array

Impact

Score:

7.8

Justification:

Profound, proven cardio-renal protection and metabolic benefits mimicking key longevity pathways.

Evidence

Grade:

A

Score:

9.5

Justification:

Multiple large-scale human RCTs show robust cardiovascular and renal benefits.

Safety

Score:

5.5

Justification:

Manageable side effects but carries risks like GU infections and rare euglycemic DKA.

Flags

• Increased risk of urinary tract and genital yeast infections is a common side effect.
• Can cause dehydration and low blood pressure; adequate hydration is crucial.
• Carries a rare but serious risk of euglycemic ketoacidosis (eDKA), even with normal glucose levels.
• Requires periodic monitoring of kidney function (eGFR).
• A rare but severe genital infection (Fournier's gangrene) is a class-wide warning.

Verdict

A powerful tool for cardio-renal protection, but requires medical supervision.

Qualifier

scope: systemic, focused on healthspan

Created

2026-04-30T23:27:43.040506Z

Ai Model

Gemini 2.5 Pro (High)